Nutritional Management of Patients with Fatty Acid Oxidation Disorders

被引:1
|
作者
Pena-Quintana, Luis [1 ,2 ]
Correcher-Medina, Patricia [2 ,3 ]
机构
[1] Univ Las Palmas Gran Canaria, Insular Materno Infantil Univ Hosp Complex, Ctr Invest Biomed Red Fisiopatol Obes & Nutr ISCII, Pediat Gastroenterol & Nutr Unit,Asociac Canaria I, Las Palmas Gran Canaria 35016, Spain
[2] Asociac Espanola Estudio Errores Congenitos Metab, Majadahonda 28221, Spain
[3] Hosp Univ & Politecn La Fe, Metab & Nutr Unit, Valencia 46026, Spain
关键词
fatty acid oxidation disorders; energy metabolism; inborn errors of metabolism; fatty acid oxidation; intrahepatic lipids; hypoglycaemia; myopathy; cardiomyopathy; rhabdomyolysis; triheptanoin; COA DEHYDROGENASE LCHAD; OPTIMAL DIETARY THERAPY; CHAIN; CHILDREN; TRIHEPTANOIN; CONSENSUS; EXERCISE;
D O I
10.3390/nu16162707
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Treatment of fatty acid oxidation disorders is based on dietary, pharmacological and metabolic decompensation measures. It is essential to provide the patient with sufficient glucose to prevent lipolysis and to avoid the use of fatty acids as fuel as far as possible. Dietary management consists of preventing periods of fasting and restricting fat intake by increasing carbohydrate intake, while maintaining an adequate and uninterrupted caloric intake. In long-chain deficits, long-chain triglyceride restriction should be 10% of total energy, with linoleic acid and linolenic acid intake of 3-4% and 0.5-1% (5/1-10/1 ratio), with medium-chain triglyceride supplementation at 10-25% of total energy (total MCT+LCT ratio = 20-35%). Trihepatnoin is a new therapeutic option with a good safety and efficacy profile. Patients at risk of rhabdomyolysis should ingest MCT or carbohydrates or a combination of both 20 min before exercise. In medium- and short-chain deficits, dietary modifications are not advised (except during exacerbations), with MCT contraindicated and slow sugars recommended 20 min before any significant physical exertion. Parents should be alerted to the need to increase the amount and frequency of carbohydrate intake in stressful situations. The main measure in emergency hospital treatment is the administration of IV glucose. The use of carnitine remains controversial and new therapeutic options are under investigation.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Clinical manifestations and management of fatty acid oxidation disorders
    Merritt, J. Lawrence, II
    MacLeod, Erin
    Jurecka, Agnieszka
    Hainline, Bryan
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2020, 21 (04): : 479 - 493
  • [2] Clinical manifestations and management of fatty acid oxidation disorders
    J. Lawrence Merritt
    Erin MacLeod
    Agnieszka Jurecka
    Bryan Hainline
    Reviews in Endocrine and Metabolic Disorders, 2020, 21 : 479 - 493
  • [3] Fatty acid oxidation disorders
    Rinaldo, P
    Matern, D
    ANNUAL REVIEW OF PHYSIOLOGY, 2002, 64 : 477 - 502
  • [4] Fatty acid oxidation disorders
    Merritt, J. Lawrence, II
    Norris, Marie
    Kanungo, Shibani
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (24)
  • [5] Clinical and biochemical monitoring of patients with fatty acid oxidation disorders
    Lund, Allan Meldgaard
    Skovby, Flemming
    Vestergaard, Helle
    Christensen, Mette
    Christensen, Ernst
    JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 (05) : 495 - 500
  • [6] Management of fatty acid oxidation disorders: A survey of current treatment strategies
    Solis, JO
    Singh, RH
    JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 2002, 102 (12) : 1800 - 1803
  • [7] Pathophysiology of fatty acid oxidation disorders
    Bennett, M. J.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 (05) : 533 - 537
  • [8] The effect of valinomycin in fibroblasts from patients with fatty acid oxidation disorders
    Erlingsson, Uzochi Chimdinma Ndukwe
    Iacobazzi, Francesco
    Liu, Aiping
    Ardon, Orly
    Pasquali, Marzia
    Longo, Nicola
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 437 (04) : 637 - 641
  • [9] No effect of resveratrol on exercise capacity in patients with fatty acid oxidation disorders
    Storgaard, J.
    Loekken, N.
    Madsen, K.
    Laforet, P.
    Voermans, N.
    Gerrit, V.
    Vissing, J.
    Oerngreen, M.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S111 - S112
  • [10] Long-Chain Fatty Acid Oxidation Disorders and Current Management Strategies
    Vockley, Jerry
    AMERICAN JOURNAL OF MANAGED CARE, 2020, 26 (07): : S147 - S154